US Stocks Movement | AstraZeneca (AZN.US) rises over 2% as Goldman Sachs is bullish, raising price target to $99
According to Jinse Finance APP, on Wednesday, AstraZeneca (AZN.US) rose more than 2%, closing at $81.99. Recently, Goldman Sachs released a research report stating that AstraZeneca announced positive results for Baxdrostat in the Phase III BaxHTN clinical trial at the 2025 European Society of Cardiology (ESC) annual meeting. Baxdrostat demonstrated strong efficacy in treating hypertension during the clinical trial and is expected to bring AstraZeneca sales opportunities worth several billions of dollars. Goldman Sachs has given AstraZeneca a "Buy" rating, with a 12-month target price of $99. This target price represents an upside of about 23% compared to the stock's closing price of $80.19 on Tuesday.
According to the information, Baxdrostat is a highly selective aldosterone synthase inhibitor (ASI) that targets one of the hormones responsible for increased blood pressure and elevated cardiovascular and renal risks. Currently, the drug is undergoing clinical trials worldwide, with more than 20,000 patients enrolled. The trials include monotherapy for hypertension and primary aldosteronism, combination therapy with dapagliflozin for chronic kidney disease and hypertension, as well as prevention of heart failure in hypertensive patients. It is reported that Baxdrostat is expected to be approved in the US and Europe in the first half of 2026, becoming the world's first marketed aldosterone synthase inhibitor (ASI) antihypertensive drug.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UK factory output posts strongest growth in over two years! Cost pressures are rising again, further reinforcing the Bank of England's rate hike path this week
Orders and production in the UK are recovering at an accelerating pace, but rising input costs and stagnant hiring mean that improved demand has not yet smoothly translated into business profits and employment growth.
Acquisition rumors of Global Payments spark valuation discussions! "Big Short" Burry: The real opportunity lies in Fiserv (FISV.US) and PayPal (PYPL.US)
Burry believes Fiserv has a potential acquisition price of $100 to $120, offering an upside of 100% to 140% from the current price. He reiterates that PayPal is a "good pitch," while questioning the acquisition value of Global Payments.
After the Nasdaq evaporated over $2 trillion in a single month, Wall Street is starting to look for buying opportunities! Deutsche Bank upgrades its technology rating, and Goldman Sachs’s “seven signals” outline the bull narrative.
Deutsche Bank is optimistic about U.S. tech stocks, overturning its downgrade rating from three weeks ago. The bank claims that the large sell-off has created attractive buying opportunities and that most of the risks related to artificial intelligence have already been excessively priced in by the market.
NEAR Enters Bitwise Large-Cap Indexes in October Rebalance
Crypto prices
More
